Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: Synthesis of recent data

Psychopharmacology Bulletin

Volumn 42, Issue 2, 2009, Pages 5-38

  Demitrack, Mark A ^a   Thase, Michael E ^b  

^a Neuronetics   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressant; Efficacy; Major depression; Randomized clinical trial; Safety; TMS; TMS study group; Transcranial magnetic stimulation; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT;

ADJUVANT THERAPY; AGE DISTRIBUTION; ARTICLE; BRAIN CORTEX; CLINICAL TRIAL; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; HUMAN; MAJOR DEPRESSION; NERVE CELL STIMULATION; NON INVASIVE PROCEDURE; PATIENT SAFETY; PROGNOSIS; PSYCHOPHARMACOTHERAPY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 70350151342     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)